Form D · Biotechnology
Consano Bio, Inc.
Burlington, MA · CIK 0001981285
Offering snapshot reported Mar 20, 2026 · SEC filing
- Reported sold
- $34.8M Offering amount: $48.9M
- Investors reported
- 28 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 6, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 20, 2026 | Initial | $34,824,466 | No comparison | 28 | SEC filing |
| Dec 12, 2025 | Initial | $16,840,000 | No comparison | 18 | SEC filing |
| Jun 13, 2023 | Initial | $7,900,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-577172
Source: Form D, filed Mar 20, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Bill Abbington | Director |
| Jerome Adams | Director |
| Chris Centeno | Director |
| Christopher Centeno | Director |
| John Conway | Director |
| Daniel Haders | Director |
| Andrew Hall | Director, Executive |
| Clayton Hartman | Director |
| Michael Pede | Director |
| Na Regenexx Holdings, Llc | Executive |
| Wayne Schellhammer | Director, Executive |
| Joe Schiesl | Director |
| Jennifer Schmitke | Executive |
| Doug Vander Weide | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
100 Summit Drive
Burlington, MA, 01803
Burlington, MA, 01803